Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Celecoxib and Pregabalin Compared With Celecoxib Monotherapy, in Patients With Chronic Low Back Pain Having a Neuropathic Component

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have Chronic low back pain with high probability of a significant neuropathic component for 4 years or less (but no less than 3 months)~* Subjects must be in generally good health, except for the presence of chronic low back pain with a neuropathic component.~* Subjects must be literate and have the ability (unaided) to understand and use the interactive voice response system (IVRS), have daily access to a telephone or the internet in order to complete the IVRS assessments each day, perform telephone or web visits and complete all required assessments/forms~Exclusion Criteria:~* Subjects with past history of surgery for chronic low back pain.~* Subjects with past history of failure on pregabalin treatment and/or intolerance associated with pregabalin or gabapentin.~* Subjects with past history of intolerance associated with celecoxib or known hypersensitivity to celecoxib.~* Patients with anticipated need for treatment with opioid analgesics, anti-epileptic medications, SNRI antidepressants or tricyclic antidepressants to alleviate pain during the course of the study.~* Patients with chronic low back pain with a neuropathic component for more than 4 years.~* Patients with neurologic disorders unrelated to low back pain that may confuse or confound the assessment of neuropathic pain (eg, primary or secondary nerve diseases).~* Subjects considered at risk of suicide or self-harm based on investigator judgment and/or details of a risk assessment.~* Use of prohibited medications in the absence of appropriate washout periods.~* Patients with any severe pain associated with conditions other than chronic low back pain with a neuropathic component that may confound the assessment or self-evaluation of the pain due to chronic low back pain.~* Patients with diabetes with poor glycemic control (HbA1c \>8%).~* Patients with any clinically significant or unstable medical or psychiatric condition or laboratory abnormality that, in the opinion of the investigator, would compromise participation in the study~* Patients who have participated in any previous clinical trial for pregabalin or have participated in 2 or more previous clinical trials for pain related to chronic low back pain.~* Patients who are likely to require surgery during the course of the study (except minor surgery, eg, for skin conditions)~* Patients with a history of Substance Abuse as defined by DSM-IV-TR diagnostic criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): The group of patients who are randomized to receive concomitant treatment of pregabalin and celecoxib during the first study period.
- Arm B (Type: OTHER): The group of patients who are randomized to receive celecoxib monotherapy during the first study period.

Based on this trial design, predict the completion outcome and termination type (if applicable).